Market Access/ News/ News Drug-resistant epilepsy drug Ontozry backed by NICE Phil Taylor Angelini Pharma, epilepsy, HEOR, NICE, Ontozry 0 Comment NHS patients in England and Wales with drug-resistant epilepsy are in line for access to another treatment option, Share X Drug-resistant epilepsy drug Ontozry backed by NICE https://pharmaphorum.com/news/drug-resistant-epilepsy-drug-ontozry-backed-by-nice/
News/ News/ R&D Angelini and Arvelle create neurology player with $960m merger Richard Staines Angelini Pharma, cenobamate, M&A, mental health, neurology 0 Comment There’s a new player in the neurology and mental health drugs market after Italy’s Angelini Pharma merged with Share X Angelini and Arvelle create neurology player with $960m merger https://pharmaphorum.com/news/angelini-and-arvelle-create-neurology-player-with-960m-merger/
